Review mapping the mechanistic crosstalk between PI3K/Akt/mTOR and JAK/STAT pathways in MS neuroinflammation, identifying dual-pathway mTOR targeting as a therapeutic opportunity to reduce immune dysregulation and demyelination.
| Evidence tier | D Mechanistic / in vitro / review |
| Study type | Narrative Review |
| Model system | N/A (review) |
| Journal | Immunologic research |
| Year | 2026 |
| Peer reviewed | Yes |
| Source | DOI 10.1007/s12026-026-09808-9 |
Multiple Sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder characterized by demyelination, axonal injury, and progressive neurological dysfunction. Emerging evidence identifies PI3K/Akt/mTOR and JAK/STAT pathways as interconnected regulators of neuroinflammation and immune dysregulation in MS.
| Intervention | mTOR inhibitors (proposed therapeutic) |
| Target | PI3K/Akt/mTOR-JAK/STAT axis |
| Model | N/A (review) |
| Effect | PI3K/Akt/mTOR-JAK/STAT crosstalk drives neuroinflammation in MS; mTOR inhibition proposed as treatment |